An insight into the prevalence of NAFLD and NASH. Prof Abdelmalek, USA
Prof. M. F. Abdelmalek- 0 mins
Video An insight into the prevalence of NAFLD and NASH. Prof Abdelmalek, USA -Copyright ©2022 by PanNash™ Initiative - All rights reserved.
- Prof. M. F. Abdelmalek
- May 10, 2019
- More Epidemiology
Would you like to read more?
Prof. M. F. Abdelmalek
From NAFLD to NASH: determining disease progression and regression rates
The spectrum of non-alcoholic fatty liver disease (NAFLD) is divisible into three stages: 1) NAFL, 2) non-alcoholic steatohepatitis (NASH), NAFLD’s…
The power of PPARs in NASH-associated microvascular dysfunction
Hepatic microvascular dysfunction is central to the development and progression of nonalcoholic steatohepatitis (NASH), the inflammatory subtype of nonalcoholic fatty…
Phospholipid depletion and NAFLD pathophysiology: findings from lipidomics
Along with its association with metabolic syndrome, NAFLD is closely linked with mixed dyslipidaemia (reduced high-density lipoprotein cholesterol (HDL-C) and…
Noninvasive tests for NAFLD: where are we now?
Up to 30% of patients with non-alcoholic fatty liver disease (NAFLD) progress to non-alcoholic steatohepatitis (NASH), significantly increasing their risk…
Cardiovascular disease in MAFLD versus NAFLD: a review
Changing the terminology from NAFLD, non-alcoholic fatty liver disease, to MAFLD, metabolic dysfunction-associated fatty liver disease, has been an ongoing…
NASH and its clinical trials: exciting recent developments
Patients with non-alcoholic fatty liver disease (NAFLD) are at risk of progressing to inflammatory non-alcoholic steatohepatitis (NASH), a NAFLD subtype…
The “Perfect” NASH Biomarker: an Unrealistic Pursuit?
Seeking the perfect NASH biomarker may be unrealistic; versatility is key. A diverse biomarker pool adapts to varied clinical contexts…
Costs of Care for Non-Alcoholic Steatohepatitis in the United States: a Review
The rising healthcare costs of NASH highlight the need for early intervention. Higher FIB-4 scores correlate with increased healthcare expenses.…
Non-Invasive Tests and Their Cut-Offs for Assessing Fibrosis: a Review
Heterogeneity in cut-off points for non-invasive fibrosis tests impacts NAFLD risk stratification. Standardized guidelines could improve consistency and accuracy in…
Physician-Stated vs Clinically-Derived Reference Fibrosis Score in NASH: a Review
Physicians often underestimate or overestimate fibrosis severity in NASH, leading to concerns about appropriate treatment. Standardized interpretations of risk stratification…
T2D-Related Complications and its Impact on Fibrosis Levels: an Emerging Association?
Patients with T2D complications have a 4.5x greater risk of developing fibrosis, independent of HbA1c levels. FIB-4 index can help…
Non-Invasive Tests to Stratify NAFLD Based on Liver-Related Events: a Review
FIB4 and VCTE show promise in predicting prognosis for NAFLD patients. These non-invasive tests offer an alternative to liver biopsies…
Video SERIES
SUBSCRIBE & FOLLOW US
Subscribe Our Newsletter To Get the Lastest Updates
